A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

  1. Rugo, H.S.
  2. Trédan, O.
  3. Ro, J.
  4. Morales, S.M.
  5. Campone, M.
  6. Musolino, A.
  7. Afonso, N.
  8. Ferreira, M.
  9. Park, K.H.
  10. Cortes, J.
  11. Tan, A.R.
  12. Blum, J.L.
  13. Eaton, L.
  14. Gause, C.K.
  15. Wang, Z.
  16. Im, E.
  17. Mauro, D.J.
  18. Jones, M.B.
  19. Denker, A.
  20. Baselga, J.
Revue:
Breast Cancer Research and Treatment

ISSN: 1573-7217 0167-6806

Année de publication: 2017

Volumen: 165

Número: 3

Pages: 601-609

Type: Article

DOI: 10.1007/S10549-017-4375-5 GOOGLE SCHOLAR